Drugs / Flu Quadrivalent influenza vaccine (15 μg HA)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05045144 | Oct 2021 → Jun 2022 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu Quadrivalent influenza vaccine (15 μg HA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05045144 ↗ |
| Known as | Flu D-QIV | “In addition, this study will evaluate immunogenicity, safety and reactogenicity from co-administration of RSV MAT vaccine and GSK's quadrivalent seasonal influenza (Flu D-QIV) vaccine.” NCT05045144 ↗ |
| Modality | Vaccine | “A single-dose quadrivalent influenza vaccine (FLU-D-QIV)” PMID 38970327 ↗ Feb 2025 |
| Route | Intramuscular | “A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).” NCT05045144 ↗ |